[Treatment of Kasabach Merritt syndrome].
Lanau Arilla
M P
MP
Servicio de Hematología y Hemoterapia, Hospital Miguel Servet, Zaragoza.
García Erce
J A
JA
Torres Gómez
M
M
Lucía Cuesta
J F
JF
Giralt Raichs
M
M
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004621:Embolization, Therapeutic; D006391:Hemangioma / Q000150:complications* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007231:Infant, Newborn; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D017713:Platelet Transfusion; D013577:Syndrome; D013921:Thrombocytopenia / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy
D000305:Adrenal Cortex Hormones; D001779:Blood Coagulation Factors; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D010975:Platelet Aggregation Inhibitors; D003520:Cyclophosphamide